Cargando…
The C18:3n6/C22:4n6 ratio is a good lipid marker of chronic kidney disease (CKD) progression
BACKGROUND: Chronic kidney disease (CKD) is a major challenge for public health due to increased risk of cardiovascular diseases (CVD) and premature death. The aim of this study was to determine the clinical picture of FA and the course of the pathophysiological mechanisms of CKD. METHODS: The study...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164198/ https://www.ncbi.nlm.nih.gov/pubmed/32303226 http://dx.doi.org/10.1186/s12944-020-01258-y |
_version_ | 1783523246158643200 |
---|---|
author | Szczuko, Małgorzata Kaczkan, Małgorzata Małgorzewicz, Sylwia Rutkowski, Przemysław Dębska-Ślizień, Alicja Stachowska, Ewa |
author_facet | Szczuko, Małgorzata Kaczkan, Małgorzata Małgorzewicz, Sylwia Rutkowski, Przemysław Dębska-Ślizień, Alicja Stachowska, Ewa |
author_sort | Szczuko, Małgorzata |
collection | PubMed |
description | BACKGROUND: Chronic kidney disease (CKD) is a major challenge for public health due to increased risk of cardiovascular diseases (CVD) and premature death. The aim of this study was to determine the clinical picture of FA and the course of the pathophysiological mechanisms of CKD. METHODS: The study involved 149 patients with CKD and a control group including 43 people. Fatty acid profiles were investigated using gas chromatography. A total of 30 fatty acids and their derivatives were identified and quantified. The omega3, omega6, SFA, MUFA, and PUFA fatty acid contents were calculated. The correlation matrix was obtained for parameters relating to patients with CKD vs. FA, taking patients’ sex into consideration. The index C18:3n6/C22:4n6 was calculated according to the length of the treatment. Statistica 12.0 software (Tulsa, Oklahoma, USA) was used for the statistical analyses. RESULTS: The results showed decreased levels of total PUFA and increased concentrations of MUFA, including the activation of the palmitic and oleic acid pathway. An increase in the levels of n-6 9C22: 4n6 family fatty acids in all the patients and a reduction in the n-3 family (EPA, DHA) were observed. C18:3n6 was negatively correlated and C22:4n6 was positively correlated with the duration of the treatment. The index C18:3n6/C22:4n6 was defined as a new marker in the progression of the disease. Moreover, the index C18:3n6/ C22:4n6 was drastically decreased in later period. Nervonic acid was higher in the CKD group. In the group of men with CKD, there was a negative correlation between the excretion of K+, anthropometric measurements, and the levels of EPA and DHA. CONCLUSIONS: The course of inflammation in CKD occurs through the decrease in PUFA and the synthesis of MUFA. The dominating cascade of changes is the elongation of GLA-C18:3n6 into DGLA-C20:3n6 and AA-C20:4n6. As CKD progresses, along with worsening anthropometrical parameters and increased secretion of potassium, the activity of Ʌ6-desaturase decreases, reducing the synthesis of EPA and DHA. The synthesis of AdA-C22:4n6 increases and the ratio C18:3n6/C22:4n6 drastically decreases after 5 years. This parameter can be used to diagnose disease progression. |
format | Online Article Text |
id | pubmed-7164198 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-71641982020-04-22 The C18:3n6/C22:4n6 ratio is a good lipid marker of chronic kidney disease (CKD) progression Szczuko, Małgorzata Kaczkan, Małgorzata Małgorzewicz, Sylwia Rutkowski, Przemysław Dębska-Ślizień, Alicja Stachowska, Ewa Lipids Health Dis Research BACKGROUND: Chronic kidney disease (CKD) is a major challenge for public health due to increased risk of cardiovascular diseases (CVD) and premature death. The aim of this study was to determine the clinical picture of FA and the course of the pathophysiological mechanisms of CKD. METHODS: The study involved 149 patients with CKD and a control group including 43 people. Fatty acid profiles were investigated using gas chromatography. A total of 30 fatty acids and their derivatives were identified and quantified. The omega3, omega6, SFA, MUFA, and PUFA fatty acid contents were calculated. The correlation matrix was obtained for parameters relating to patients with CKD vs. FA, taking patients’ sex into consideration. The index C18:3n6/C22:4n6 was calculated according to the length of the treatment. Statistica 12.0 software (Tulsa, Oklahoma, USA) was used for the statistical analyses. RESULTS: The results showed decreased levels of total PUFA and increased concentrations of MUFA, including the activation of the palmitic and oleic acid pathway. An increase in the levels of n-6 9C22: 4n6 family fatty acids in all the patients and a reduction in the n-3 family (EPA, DHA) were observed. C18:3n6 was negatively correlated and C22:4n6 was positively correlated with the duration of the treatment. The index C18:3n6/C22:4n6 was defined as a new marker in the progression of the disease. Moreover, the index C18:3n6/ C22:4n6 was drastically decreased in later period. Nervonic acid was higher in the CKD group. In the group of men with CKD, there was a negative correlation between the excretion of K+, anthropometric measurements, and the levels of EPA and DHA. CONCLUSIONS: The course of inflammation in CKD occurs through the decrease in PUFA and the synthesis of MUFA. The dominating cascade of changes is the elongation of GLA-C18:3n6 into DGLA-C20:3n6 and AA-C20:4n6. As CKD progresses, along with worsening anthropometrical parameters and increased secretion of potassium, the activity of Ʌ6-desaturase decreases, reducing the synthesis of EPA and DHA. The synthesis of AdA-C22:4n6 increases and the ratio C18:3n6/C22:4n6 drastically decreases after 5 years. This parameter can be used to diagnose disease progression. BioMed Central 2020-04-17 /pmc/articles/PMC7164198/ /pubmed/32303226 http://dx.doi.org/10.1186/s12944-020-01258-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Szczuko, Małgorzata Kaczkan, Małgorzata Małgorzewicz, Sylwia Rutkowski, Przemysław Dębska-Ślizień, Alicja Stachowska, Ewa The C18:3n6/C22:4n6 ratio is a good lipid marker of chronic kidney disease (CKD) progression |
title | The C18:3n6/C22:4n6 ratio is a good lipid marker of chronic kidney disease (CKD) progression |
title_full | The C18:3n6/C22:4n6 ratio is a good lipid marker of chronic kidney disease (CKD) progression |
title_fullStr | The C18:3n6/C22:4n6 ratio is a good lipid marker of chronic kidney disease (CKD) progression |
title_full_unstemmed | The C18:3n6/C22:4n6 ratio is a good lipid marker of chronic kidney disease (CKD) progression |
title_short | The C18:3n6/C22:4n6 ratio is a good lipid marker of chronic kidney disease (CKD) progression |
title_sort | c18:3n6/c22:4n6 ratio is a good lipid marker of chronic kidney disease (ckd) progression |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164198/ https://www.ncbi.nlm.nih.gov/pubmed/32303226 http://dx.doi.org/10.1186/s12944-020-01258-y |
work_keys_str_mv | AT szczukomałgorzata thec183n6c224n6ratioisagoodlipidmarkerofchronickidneydiseaseckdprogression AT kaczkanmałgorzata thec183n6c224n6ratioisagoodlipidmarkerofchronickidneydiseaseckdprogression AT małgorzewiczsylwia thec183n6c224n6ratioisagoodlipidmarkerofchronickidneydiseaseckdprogression AT rutkowskiprzemysław thec183n6c224n6ratioisagoodlipidmarkerofchronickidneydiseaseckdprogression AT debskaslizienalicja thec183n6c224n6ratioisagoodlipidmarkerofchronickidneydiseaseckdprogression AT stachowskaewa thec183n6c224n6ratioisagoodlipidmarkerofchronickidneydiseaseckdprogression AT szczukomałgorzata c183n6c224n6ratioisagoodlipidmarkerofchronickidneydiseaseckdprogression AT kaczkanmałgorzata c183n6c224n6ratioisagoodlipidmarkerofchronickidneydiseaseckdprogression AT małgorzewiczsylwia c183n6c224n6ratioisagoodlipidmarkerofchronickidneydiseaseckdprogression AT rutkowskiprzemysław c183n6c224n6ratioisagoodlipidmarkerofchronickidneydiseaseckdprogression AT debskaslizienalicja c183n6c224n6ratioisagoodlipidmarkerofchronickidneydiseaseckdprogression AT stachowskaewa c183n6c224n6ratioisagoodlipidmarkerofchronickidneydiseaseckdprogression |